Technical Analysis for RPRX - Royalty Pharma plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.81% | |
| Volume Surge | Other | 0.81% | |
| Outside Day | Range Expansion | 0.81% | |
| Up 3 Days in a Row | Strength | 0.81% | |
| Gapped Down | Weakness | 0.81% | |
| Oversold Stochastic | Weakness | 0.81% | |
| Lower Bollinger Band Walk | Weakness | 1.63% | |
| Oversold Stochastic | Weakness | 1.63% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 20 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Up 1% | about 22 hours ago |
| Rose Above Previous Day's High | about 22 hours ago |
| Rose Above Previous Day's High | 2 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/06/2024
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.9227 |
| 52 Week Low | 24.8016 |
| Average Volume | 2,312,819 |
| 200-Day Moving Average | 27.59 |
| 50-Day Moving Average | 27.14 |
| 20-Day Moving Average | 26.40 |
| 10-Day Moving Average | 25.90 |
| Average True Range | 0.54 |
| RSI (14) | 44.75 |
| ADX | 13.12 |
| +DI | 16.57 |
| -DI | 16.85 |
| Chandelier Exit (Long, 3 ATRs) | 26.51 |
| Chandelier Exit (Short, 3 ATRs) | 26.72 |
| Upper Bollinger Bands | 27.53 |
| Lower Bollinger Band | 25.27 |
| Percent B (%b) | 0.42 |
| BandWidth | 8.55 |
| MACD Line | -0.40 |
| MACD Signal Line | -0.40 |
| MACD Histogram | -0.0022 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.96 | ||||
| Resistance 3 (R3) | 26.90 | 26.59 | 26.83 | ||
| Resistance 2 (R2) | 26.59 | 26.41 | 26.62 | 26.79 | |
| Resistance 1 (R1) | 26.41 | 26.29 | 26.50 | 26.47 | 26.75 |
| Pivot Point | 26.10 | 26.10 | 26.15 | 26.13 | 26.10 |
| Support 1 (S1) | 25.92 | 25.92 | 26.01 | 25.98 | 25.69 |
| Support 2 (S2) | 25.61 | 25.80 | 25.64 | 25.65 | |
| Support 3 (S3) | 25.43 | 25.61 | 25.61 | ||
| Support 4 (S4) | 25.49 |
